A male presenting with respiratory distress is put on a ventilator. Tracheal culture was obtained and sent for diagnosis. In the meanwhile, he was empirically staed on amikacin and ceftriaxone. Culture repo after 48 hrs shows growth of Klebsiella pneumoniae which is ESBL +ve on antimicrobial susceptibility testing. The modification needed in his antibiotic treatment is:

**Core Concept**
Klebsiella pneumoniae is a gram-negative bacterium that can produce extended-spectrum beta-lactamases (ESBLs), which confer resistance to a wide range of beta-lactam antibiotics, including penicillins and cephalosporins. ESBL-producing bacteria often require alternative antibiotics with a different mechanism of action.

**Why the Correct Answer is Right**
The patient's ESBL-producing Klebsiella pneumoniae requires modification of his antibiotic treatment to avoid beta-lactam antibiotics. Amikacin, aminoglycoside antibiotic, is effective against gram-negative bacteria but may not be sufficient as monotherapy for ESBL-producing Klebsiella pneumoniae. However, a combination of an aminoglycoside like amikacin with a carbapenem, which is a broad-spectrum beta-lactam antibiotic that is generally resistant to ESBL degradation, would be more effective. In this case, the modification needed is to add a carbapenem to the treatment regimen.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because adding another cephalosporin (such as ceftriaxone) would not be effective against ESBL-producing Klebsiella pneumoniae.

**Option B:** This option is incorrect because adding another aminoglycoside (such as gentamicin) would not provide a synergistic effect against ESBL-producing Klebsiella pneumoniae.

**Option C:** This option is incorrect because adding a fluoroquinolone (such as ciprofloxacin) would not be effective against ESBL-producing Klebsiella pneumoniae due to increasing resistance rates.

**Clinical Pearl / High-Yield Fact**
Carbapenems, such as imipenem or meropenem, are considered the treatment of choice for ESBL-producing gram-negative bacteria, including Klebsiella pneumoniae. However, carbapenem resistance is emerging, and susceptibility testing should be performed to guide treatment.

**Correct Answer:** D.

✓ Correct Answer: C. Replace ceftriaxone with imipenem